ArticleThe European respiratory journal2022
Rifapentine access in Europe: growing concerns over key tuberculosis treatment component.
Abstract readLetter
In one paragraph
Article in The European respiratory journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Efficacy and safety of an innovative short-course regimen containing clofazimine for treatment of drug-susceptible tuberculosis: a clinical trial.Emerging microbes & infections · 2023Trial
- What is new in tuberculosis?Clinical medicine (London, England) · 2026Review
- Mental health management in the context of TB care in the WHO European Region: a consensus statement.IJTLD open · 2026Review
- Latent tuberculosis infection screening and treatment outcomes in healthcare workers in Irish hospitals: a multi-centre cohort study.Infection control and hospital epidemiology · 2026Article
- Is the unavailability of rifapentine holding back the end TB strategy in Europe? Implication for tuberculosis control among migrants and refugees.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- One-Month Rifapentine-Isoniazid Regimen Versus Six-Month Isoniazid Monotherapy for Latent Tuberculosis: Experience from a Reference Center.Medicina (Kaunas, Lithuania) · 2026Observational
- Article
- Article
- TBSure: an ESGMYC survey of pediatric TB management practices in high-income countries.Frontiers in public health · 2026Article
- Tuberculosis prevention: current strategies and future directions.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2024Review
- TB prevention activities in the WHO European Region.IJTLD open · 2024Article
- Conjugated hyperbilirubinemia associated with accidental rifapentine overdose.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2024Article
- The Challenges of Tuberculosis Management beyond Professional Competence: Insights from Tuberculosis Outbreaks among Ethiopian Immigrants in Israel.Tropical medicine and infectious disease · 2024Article
- Tuberculosis in Spain: An opinion paper.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Review
- Prioritizing persons deprived of liberty in global guidelines for tuberculosis preventive treatment.PLoS medicine · 2023Article
- ERS International Congress 2022: highlights from the Respiratory Infections Assembly.ERJ open research · 2023Article
- Ending tuberculosis in Europe - resetting the course in the post-COVID-19 era.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Article
- Availability and costs of medicines for the treatment of tuberculosis in Europe.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023Article
- Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally.The European respiratory journal · 2022Article
Corrections and comments
- Commented on by
Authors and funding
17 authors.
Lorenzo GuglielmettiSorbonne Université, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, Paris, France lorenzo.guglielmetti@aphp.fr.ORCID 0000-0003-0886-9635
Gunar GüntherDepartment of Pulmonology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Claude LeuDepartment of Pulmonology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Daniela CirilloWHO Collaborating Centre and TB Supranational Reference Laboratory, San Raffaele Scientific Institute, Milano, Italy.ORCID 0000-0001-6415-1535
Raquel DuarteEpidemiology Research Unit (EpiUnit), Institute of Public Health, University of Porto, Porto, Portugal.ORCID 0000-0003-2257-3099
Alberto L Garcia-BasteiroCentro de Investigação em Saúde de Manhiça (CISM), Maputo, Moçambique.
Delia GolettiNational Institute for Infectious Diseases L. Spallanzani-IRCCS, Rome, Italy.ORCID 0000-0001-8360-4376
Mateja JankovicClinic for Lung Diseases, University of Zagreb School of Medicine and University Hospital Center Zagreb, Zagreb, Croatia.ORCID 0000-0002-0171-764X
Liga KuksaRiga East University Hospital, TB and Lung Disease Centre, Riga, Latvia.
Florian P MaurerNational and Supranational Reference Center for Mycobacteria, Research Center Borstel, Borstel, Germany.ORCID 0000-0001-8353-5964
Frédéric MéchaïAPHP, Infectious Disease Unit, Avicenne Hospital, Université Paris 13, IAME, INSERM, Bobigny, France.
Simon TiberiBlizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University, London, UK.
Frank van LethVU University, Department of Health Sciences, Amsterdam, The Netherlands.ORCID 0000-0002-5490-8968
Nicolas VezirisAPHP, Groupe Hospitalier Universitaire Sorbonne Université, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France.ORCID 0000-0001-5660-6544
Christoph LangeGerman Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany.ORCID 0000-0002-9691-4741
Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and
Tuberculosis Network European Trials group (TBnet)
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antibiotics, AntitubercularTuberculosisAntitubercular AgentsDrug Therapy, CombinationEuropeHumansRifampinAntibiotics, AntitubercularAntitubercular AgentsRifampinrifapentine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.